Non-Hodgkin's Lymphoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin; Child, Only Interventions: Other: intrathecal rituximab Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201
Conditions: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Interventions: Drug: CN201 Sponsors: Curon Biopharmaceutical (Shanghai) Co.,Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2024 Category: Research Source Type: clinical trials

a Phase I Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Conditions: B Cell Lymphoma; Non Hodgkin Lymphoma Interventions: Biological: MC-1-50 Sponsors: Chongqing Precision Biotech Co., Ltd; Peking University Cancer Hospital& Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2023 Category: Research Source Type: clinical trials

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Conditions: B Cell Lymphoma; Non Hodgkin Lymphoma Interventions: Biological: MC-1-50 Sponsors: Chongqing Precision Biotech Co., Ltd; Peking University Cancer Hospital& Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2023 Category: Research Source Type: clinical trials

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Conditions: CD30-Positive Diffuse Large B-Cell Lymphoma; Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type; Anaplastic Large Cell Lymphoma, ALK-Positive; Peripheral T-cell Lymphoma; Anaplastic Large Cell Lymphoma, ALK-negative; Non-Hodgkin Lymphoma; Hodgkin Lymphoma Interventions: Biological: C7R.CD30.CAR-EBVST cells Sponsors: Baylor College of Medicine; The Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia; Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Interventions: Biological: AUTO1 Sponsors: Autolus Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials

Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
Conditions: Lymphoma, Non-Hodgkin Interventions: Drug: immunochemotherapies Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2023 Category: Research Source Type: clinical trials

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
Conditions: Non-hodgkin Lymphoma,B Cell Interventions: Biological: CART-19 and 20 cells; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: Henan Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Conditions: Follicular Lymphoma; Refractory B-Cell Lymphoma; Relapsed Non-Hodgkin Lymphoma Interventions: Drug: Chidamide combined with Linperlisib Sponsors: The First Affiliated Hospital of Xiamen University; Fujian Provincial Hospital; Fujian Cancer Hospital; Zhangzhou Affiliated Hospital of Fujian Medical University; Jieyang People ' s Hospital; Dongguan People ' s Hospital; Huizhou Municipal Central Hospital; The First Affiliated Hospital with Nanjing Medical University; Sun Yat-sen University; Shanxi Province Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 6, 2023 Category: Research Source Type: clinical trials

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
Conditions: Non-hodgkin Lymphoma,B Cell Interventions: Other: Chimeric Antigen Receptor T-cells (CAR-T) therapy Sponsors: Fondazione Italiana Linfomi - ETS; Kite, A Gilead Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2023 Category: Research Source Type: clinical trials

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Conditions: Hematologic Malignancy; Leukemia; Lymphoma; Acute Lymphocytic Leukemia; ALL; Acute Myelogenous Leukemia; AML; Chronic Myelogenous Leukemia; CML; Myeloproliferative Neoplasm; Non Hodgkin Lymphoma; Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Burkitt Lymphoma; T-cell Lymphoma; B Cell Lymphoma; Peripheral T Cell Lymphoma; Cutaneous B-Cell Lymphoma Interventions: Other: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care. Sponsors: Children ' s Hospit...
Source: ClinicalTrials.gov - November 14, 2023 Category: Research Source Type: clinical trials

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Conditions: NHL; Multiple Myeloma; Blood Cancer; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma Interventions: Drug: IDP-023; Drug: Rituximab; Drug: Daratumumab; Drug: Interleukin-2; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Mesna Sponsors: Indapta Therapeutics, INC. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Conditions: Non Hodgkin Lymphoma Interventions: Other: Long-term Follow-Up Sponsors: Miltenyi Biomedicine GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Conditions: Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma Interventions: Radiation: Comprehensive Ablative Bridging Irradiation (CABI); Biological: Chimeric Antigen Receptor T-Cell Therapy Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Kite, A Gilead Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin's Lymphoma
Conditions: B-cell Non-Hodgkin ' s Lymphoma Interventions: Drug: SHR-A1912; R-Chemo; Drug: SHR-A1912; R-Chemo Sponsors: Shanghai Hengrui Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials